Regal Investment Advisors LLC lifted its stake in Gilead Sciences, Inc. (NASDAQ:GILD – Get Rating) by 2.1% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 22,256 shares of the biopharmaceutical company's stock after purchasing an additional 461 shares during the quarter. Regal Investment Advisors LLC's holdings in Gilead Sciences were worth $1,373,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other hedge funds have also made changes to their positions in GILD. JFS Wealth Advisors LLC lifted its position in shares of Gilead Sciences by 68.1% in the third quarter. JFS Wealth Advisors LLC now owns 400 shares of the biopharmaceutical company's stock worth $25,000 after purchasing an additional 162 shares in the last quarter. Pacifica Partners Inc. raised its position in Gilead Sciences by 179.7% during the third quarter. Pacifica Partners Inc. now owns 414 shares of the biopharmaceutical company's stock valued at $26,000 after acquiring an additional 266 shares in the last quarter. Horan Securities Inc. raised its position in Gilead Sciences by 217.9% during the third quarter. Horan Securities Inc. now owns 461 shares of the biopharmaceutical company's stock valued at $28,000 after acquiring an additional 316 shares in the last quarter. Capital Advisors Ltd. LLC raised its position in Gilead Sciences by 29.4% during the third quarter. Capital Advisors Ltd. LLC now owns 607 shares of the biopharmaceutical company's stock valued at $37,000 after acquiring an additional 138 shares in the last quarter. Finally, Wagner Wealth Management LLC bought a new position in Gilead Sciences during the second quarter valued at approximately $42,000. 78.72% of the stock is owned by hedge funds and other institutional investors.
Get Gilead Sciences alerts:Insider Activity
In other news, insider Merdad Parsey sold 12,984 shares of the business's stock in a transaction on Wednesday, March 1st. The shares were sold at an average price of $79.96, for a total value of $1,038,200.64. Following the sale, the insider now owns 70,130 shares in the company, valued at approximately $5,607,594.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.16% of the stock is owned by corporate insiders.
Gilead Sciences Stock Up 0.7 %
GILD opened at $79.50 on Friday. Gilead Sciences, Inc. has a fifty-two week low of $57.17 and a fifty-two week high of $89.74. The company has a debt-to-equity ratio of 1.14, a current ratio of 1.29 and a quick ratio of 1.15. The firm's fifty day moving average price is $83.89 and its two-hundred day moving average price is $77.84. The company has a market capitalization of $99.14 billion, a P/E ratio of 21.78, a P/E/G ratio of 0.94 and a beta of 0.38.
Gilead Sciences (NASDAQ:GILD – Get Rating) last posted its quarterly earnings results on Thursday, February 2nd. The biopharmaceutical company reported $1.67 earnings per share for the quarter, topping analysts' consensus estimates of $1.50 by $0.17. Gilead Sciences had a net margin of 16.83% and a return on equity of 44.46%. The firm had revenue of $7.39 billion for the quarter, compared to the consensus estimate of $6.63 billion. During the same quarter in the previous year, the company earned $0.69 earnings per share. The business's revenue was up 2.0% compared to the same quarter last year. On average, analysts anticipate that Gilead Sciences, Inc. will post 6.84 EPS for the current year.
Gilead Sciences Increases Dividend
The company also recently announced a quarterly dividend, which will be paid on Thursday, March 30th. Stockholders of record on Wednesday, March 15th will be paid a $0.75 dividend. This represents a $3.00 annualized dividend and a dividend yield of 3.77%. The ex-dividend date is Tuesday, March 14th. This is an increase from Gilead Sciences's previous quarterly dividend of $0.73. Gilead Sciences's payout ratio is currently 80.00%.
Analyst Upgrades and Downgrades
Several brokerages recently weighed in on GILD. Mizuho raised their price objective on shares of Gilead Sciences from $88.00 to $101.00 and gave the company a "buy" rating in a research report on Tuesday, February 14th. Wells Fargo & Company raised their price objective on shares of Gilead Sciences from $75.00 to $90.00 and gave the company an "equal weight" rating in a research report on Tuesday, January 3rd. SVB Leerink lifted their price target on shares of Gilead Sciences from $81.00 to $91.00 and gave the company a "market perform" rating in a research report on Friday, February 3rd. Royal Bank of Canada dropped their price target on shares of Gilead Sciences from $87.00 to $86.00 and set a "sector perform" rating on the stock in a research report on Monday, March 6th. Finally, Robert W. Baird lifted their price target on shares of Gilead Sciences from $69.00 to $80.00 in a research report on Friday, February 3rd. Nine analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $89.40.
Gilead Sciences Company Profile
(Get Rating)
Gilead Sciences, Inc is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.
Featured Stories
- Get a free copy of the StockNews.com research report on Gilead Sciences (GILD)
- MarketBeat Week in Review – 3/6 – 3/10
- 2 Offshore Drilling Stocks Set to Extract Big Profits
- Three Staples Stocks With Double-Digit Upside Ahead
- Can Investors Trust Consumers to Lift American Outdoor Brands?
- How to Buy High Yielding Dividend Stocks
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.